[go: up one dir, main page]

RU94026856A - Nootropic and tranquilizing agent - Google Patents

Nootropic and tranquilizing agent

Info

Publication number
RU94026856A
RU94026856A RU94026856/14A RU94026856A RU94026856A RU 94026856 A RU94026856 A RU 94026856A RU 94026856/14 A RU94026856/14 A RU 94026856/14A RU 94026856 A RU94026856 A RU 94026856A RU 94026856 A RU94026856 A RU 94026856A
Authority
RU
Russia
Prior art keywords
agent
weight
core
stearic acid
nootropic
Prior art date
Application number
RU94026856/14A
Other languages
Russian (ru)
Other versions
RU2065299C1 (en
Inventor
Л.Д. Смирнов
Т.А. Воронина
К.М. Дюмаев
Ю.В. Буров
Original Assignee
Акционерное общество закрытого типа "Олвик"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акционерное общество закрытого типа "Олвик" filed Critical Акционерное общество закрытого типа "Олвик"
Priority to RU94026856/14A priority Critical patent/RU2065299C1/en
Priority to PCT/RU1995/000155 priority patent/WO1996002238A1/en
Application granted granted Critical
Publication of RU2065299C1 publication Critical patent/RU2065299C1/en
Publication of RU94026856A publication Critical patent/RU94026856A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: medicine, pharmacy. SUBSTANCE: agent is prepared as tablet consisting of core containing 16.7-41.6 weight % mexidol and polymeric envelope. Core has the following auxiliary substances, weight %: white clay 16.7-33.3; potato starch 16.7-33.7; calcium stearate 0.3-0.5; stearic acid 0.3-0.5; talc 0.5-1.0, and methylcellulose 0.3-0.5. Polymeric envelope is made of, weight %: methylcellulose 25-50 with addition of Tween-80 8.3-25.0 and titanium dioxide 8.3-25.0. Agent shows the broad spectrum of therapeutic action and expressed antistress and antiamnestic effects. EFFECT: enhanced effectiveness of agent.

Claims (1)

Использование: в медицине, в частности в терапии ноотропных и транквилизирующих средств. Сущность изобретения: средство выполнено в виде таблетки, состоящей из ядра, содержащего 16,7-41,6 мас.% мексидола, и из полимерной оболочки. Ядро в качестве вспомогательных веществ содержит, мас.%: глину белую 16,7-33,3; крахмал картофельный 16,7-33,7; кальций стеариновокислый 0,3-0,5; кислоту стеариновую 0,3-0,5; тальк 0,5-1,0; метилцеллюлозу 0, 3-0,5. Полимерная оболочка выполнена из метилцеллюлозы 25-50 мас.% с добавками твина 80 8,3-25,0 мас.% и диоксида титана 8,3-25,0 мас.%. Данное средство обладает широким спектром терапевтического действия, обладает выраженным антистрессорным и антиамнестическим действием.Usage: in medicine, in particular in the treatment of nootropic and tranquilizing agents. The inventive tool is made in the form of a tablet consisting of a core containing 16.7-41.6 wt.% Mexidol, and from a polymer shell. The core as auxiliary substances contains, wt.%: White clay 16.7-33.3; potato starch 16.7-33.7; calcium stearic acid 0.3-0.5; stearic acid 0.3-0.5; talcum powder 0.5-1.0; methyl cellulose 0.3-3.5. The polymer shell is made of methyl cellulose 25-50 wt.% With the addition of tween 80 8.3-25.0 wt.% And titanium dioxide 8.3-25.0 wt.%. This tool has a wide range of therapeutic effects, has a pronounced antistress and antiamnestic effect.
RU94026856/14A 1994-07-15 1994-07-15 Nootropic and tranquilizing agent RU2065299C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU94026856/14A RU2065299C1 (en) 1994-07-15 1994-07-15 Nootropic and tranquilizing agent
PCT/RU1995/000155 WO1996002238A1 (en) 1994-07-15 1995-07-14 Neurotropic and sedative agent and a method of obtaining the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU94026856/14A RU2065299C1 (en) 1994-07-15 1994-07-15 Nootropic and tranquilizing agent

Publications (2)

Publication Number Publication Date
RU2065299C1 RU2065299C1 (en) 1996-08-20
RU94026856A true RU94026856A (en) 1996-09-27

Family

ID=20158556

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94026856/14A RU2065299C1 (en) 1994-07-15 1994-07-15 Nootropic and tranquilizing agent

Country Status (2)

Country Link
RU (1) RU2065299C1 (en)
WO (1) WO1996002238A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2668966C1 (en) * 2018-01-25 2018-10-05 "Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" (АО "ВНЦ БАВ") Complex salts of acidum acexamicum, stimulating regeneration of bone tissue, accelerating processes of reparative osteogenesis, stimulating mineralization of bone tissue in osteoporosis

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
BE1011045A3 (en) * 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
RU2145213C1 (en) * 1999-05-25 2000-02-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Pharmaceutical composition exhibiting nootropic effect and method of its preparing
RU2145855C1 (en) * 1999-05-26 2000-02-27 Смирнов Леонид Дмитриевич Drug showing anxiolytic, antialcoholic and cerebroprotective effects
RU2159615C1 (en) * 1999-11-30 2000-11-27 Смирнов Леонид Дмитриевич Medical preparation for treating narcomania
RU2168992C1 (en) * 2000-03-29 2001-06-20 Смирнов Леонид Дмитриевич Drug for treatment of patients with reactive arthritis
RU2224521C2 (en) * 2002-03-12 2004-02-27 Федеральное государственное унитарное предприятие "Московское производственное химико-фармацевтическое объединение им. Н.А.Семашко" Solid medicinal formula eliciting tranquilizing effect and method for its preparing
RU2205640C1 (en) * 2002-04-09 2003-06-10 Общество с ограниченной ответственностью "Экофарминвест" Stable mexidol-containing pharmaceutical composition
RU2284993C2 (en) * 2002-06-14 2006-10-10 Леонид Дмитриевич Смирнов 2-ethyl-6-methyl-3-oxypyrodine salts with organic carboxylic acids possessing anxiolytic, antidepressive, antihypoxic, anti-amnestic and anti-oxidative activity and method for their preparing
RU2357955C2 (en) * 2006-04-21 2009-06-10 Смирнова Лариса Каземировна Antioxidant, antihyperglycemic, hypolipidemic and antishock n-acetylcysteinate 2-ethyl-6-methyl-3-hydroxypyridine
RU2384330C2 (en) * 2007-12-18 2010-03-20 Закрытое Акционерное Общество "Канонфарма Продакшн" Composition of 3-oxy-6-methyl-2-ethylpyridine or its pharmaceutically acceptable salt in tabletted form, method for making thereof, and therapy
RU2394815C2 (en) * 2008-02-14 2010-07-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) Nitroxy-succinate 2-ethyl-6-methyl-3-oxypyridine (versions of use) and method of producing said compound
RU2405552C2 (en) * 2008-03-24 2010-12-10 Закрытое Акционерное Общество "Канонфарма Продакшн" Pharmaceutic combination of ethylmethylhydroxypyridine succinate and pyridoxine, method of its obtaining and method of treatment
RU2377237C1 (en) * 2008-04-10 2009-12-27 Закрытое акционерное общество "Медимэкс" (ЗАО "Медимэкс") 2-ethyl-6-methyl-3-hydroxyliridiniumhydroxybutanedioat expressing anti-ishemic, cerebroprotective, neurotropic and lipid-regulating activity, pharmaceutical compositions and medical product
RU2411035C2 (en) * 2008-09-24 2011-02-10 Общество с ограниченной ответственностью Научно-производственная фирма "Mikpoхiм" Modified release 6-methyl-2-ethyl-hydroxypyridine succinate dosage form
RU2398583C2 (en) * 2008-10-23 2010-09-10 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Antioxidant and antihypoxic agent of 6-methyl-2-ethyl-3-hydrohypyridine succinate
TR200904159A1 (en) * 2009-04-17 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Modified release emoxipine formulations.
TR200903548A1 (en) * 2009-05-06 2010-11-22 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral dispersing emoxipine compositions
RU2428177C1 (en) * 2010-02-12 2011-09-10 Мераб Георгиевич Пация Pharmaceutical medication
RU2613019C1 (en) * 2010-04-07 2017-03-14 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Pharmaceutical composition for parenteral administration of 2-ethyl-6-methyl-3-hydroxypyridine succinate and method of producing said composition
RU2445091C1 (en) * 2010-11-09 2012-03-20 Алексей Сергеевич Гумилевский Pharmaceutical formulation in solid dosage form and method for preparing it
RU2444359C1 (en) * 2010-12-06 2012-03-10 Общество с ограниченной ответственностью "Научно-производственная компания "ФАРМАСОФТ" (ООО "НПК "ФАРМАСОФТ") Pharmaceutical composition with 2-ethyl-6-methyl-3-hydroxypyridine succinate for oral administration and method for preparing it
RU2664453C1 (en) * 2017-11-24 2018-08-17 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Derivative of 3-hydroxypyridine with anxiolytic and nootropic effect
UA125150C2 (en) 2017-12-14 2022-01-19 Общєство С Ограніченной Отвєтствєнностью "Валєнта-Інтєллєкт" L-enantiomer 2-ethyl-6-methyl-3-hydroxypyridine L-hydroxybutanioate, which has cerebroprotective, hepatoprotective, lipid regulating, anti-airborne and neurotropic activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080127A1 (en) * 1990-04-10 1991-10-11 Peter Zimmermann Pyridines as medicaments
US5214060A (en) * 1992-04-10 1993-05-25 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5281715A (en) * 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2668966C1 (en) * 2018-01-25 2018-10-05 "Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ" (АО "ВНЦ БАВ") Complex salts of acidum acexamicum, stimulating regeneration of bone tissue, accelerating processes of reparative osteogenesis, stimulating mineralization of bone tissue in osteoporosis

Also Published As

Publication number Publication date
WO1996002238A1 (en) 1996-02-01
RU2065299C1 (en) 1996-08-20

Similar Documents

Publication Publication Date Title
RU94026856A (en) Nootropic and tranquilizing agent
MY132705A (en) Novel compounds with analgesic effect
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
DE59003587D1 (en) Diarylacetylenes, their production and use.
SE8300736D0 (en) NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS
SE9504661D0 (en) New compounds
ZA948669B (en) New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
IL116385A (en) Sulphonamides their manufacture and pharmaceutical compositions containing them
ATE175114T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AN OPIATE ANTAGONIST AND CALCIUM SALTS, THEIR USE FOR THE TREATMENT OF ENDORPHIN-MEDIATED DISEASES
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
CY1112861T1 (en) USE OF ACUTE PRODUCERS (-) (3-TRIALOMETHYLOPHOINOXY) (4-ALOFINYL) ACID FOR SURGERY TREATMENT
KR910009242A (en) Sustained release compositions for treatment of periodontal disease
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
ATE243196T1 (en) PIPERIDINE AND PYRROLIDINE
ATE156350T1 (en) PELLETS CONTAINING PEPTIDE MEDICINAL SUBSTANCES AND THEIR PRODUCTION AND USE
FR2744452B1 (en) HETEROCYCLIC BIARYLATED COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
HUP9801414A2 (en) Liquid aqueous pharmaceutical compositions comprising sodium alginate and potassium bicarbonate
TR199701121T1 (en) Benazepril or combination compositions containing benazepril and valsartan.
EA200100947A1 (en) CHEWING TABLETS WITH HIGH N-ACETYLCECHETINE CONTENT
BR1100143A (en) Compound and pharmaceutical composition.
GEP20032924B (en) Novel Furan Diarylmethylidene Derivatives, Method for Their Preparation and Pharmaceutical Composition
HUP9902135A2 (en) Use of (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)-ethyl]-4-piperidinemethanol for producing pharmaceutical compositions suitable for treatment depressive disorders and bipolar disorders
ID20967A (en) CHRISTANTS SUBSTITUTED SULFONAMIDE, THE PROCESS OF MAKING, USE AS A MEDICINE, AND PHARMACEUTICAL PROPERTIES THAT CONTAIN SUCH MATERIALS
YU13599A (en) Use of pharmaceutical composition for preparation of medicament in a gel form
MD1504F2 (en) Application of dimeticone as an active ingredient in a pharmaceutical composition for treatment of aphthae and stomatitis and pharmaceutical composition containing dimeticon

Legal Events

Date Code Title Description
QB4A Licence on use of patent

Effective date: 20080626

QZ4A Changes in the licence of a patent

Effective date: 20060525

QZ4A Changes in the licence of a patent

Effective date: 20060525

QB4A Licence on use of patent

Effective date: 20100422

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20080626

Effective date: 20101116

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20100422

Effective date: 20120425

MM4A The patent is invalid due to non-payment of fees

Effective date: 20130716